Table 6.

Strategies for bioengineered factor concentrates with modified properties in hemophilia

Target	Strategies
Increased efficiency of production	Improved secretion efficiency
	Higher mRNA stability, facilitated intracellular transport*
Increased potency and stability	Active site modifications*
	FVIIIa stabilization*
Prolonged half-life	Pegylated liposomes (FVIII)**
	Pegylation (FVIII, FIX, FVIIa)
	Polysialylation (FVIII)
	Fc fragment fusion (FIX)
	Albumin fusion (FVIIa)
Reduced immunogenicity	Porcine/human hybrids
	C1/C2 domain and inhibitor epitope mapping-driven modifications*

Notes:

^*On development by basic studies;

^**Phase II clinical trial ongoing.